• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis. A Novel Neuraminidase Deletion Mutation Conferring Resistance to Oseltamivir in Clinical Influenza A/H3N2 Virus.

Giuseppe

Emeritus
J Infect Dis. 2008 Dec 1. [Epub ahead of print]

A Novel Neuraminidase Deletion Mutation Conferring Resistance to Oseltamivir in Clinical Influenza A/H3N2 Virus.

Abed Y, Baz M, Boivin G. - Research Center in Infectious Diseases, Centre Hospitalier Universitaire de Qu?bec-Centre Hospitalier de l'Universit? Laval and Laval University, Qu?bec City, Qu?bec, Canada.

Neuraminidase (NA) mutations responsible for influenza resistance to oseltamivir vary according to the NA subtype; in influenza A/H3N2 viruses, NA-gene mutations occur predominantly at codons E119 and R292.

In an oseltamivir-resistant influenza A/H3N2 virus isolated from an immunocompromised child after 107 days of cumulative treatment, the NA gene contained 3 aa substitutions (N146K, S219T, and A272V) and a 4-aa deletion (Del245-248); reversion mutation experiments using recombinant NA proteins determined that the deletion was the sole change responsible for resistance to oseltamivir.

This study highlights the diversity of mechanisms of resistance to oseltamivir in clinical settings, reinforcing the need for novel anti-influenza strategies.

PMID: 19046066 [PubMed - as supplied by publisher
-
------
 
Back
Top